Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Fungal Phylum Microsporidia

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...

Antifungal Agents

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Urinary Tract Infection II: Pathophysiology

Urinary Tract Infection II: Pathophysiology

The pathophysiology of urinary tract infections (UTIs) encompasses several progressive stages, beginning with bacterial colonization and culminating in potential systemic complications if untreated. UTIs are primarily initiated by bacteria, such as Escherichia coli, which often originate from the gastrointestinal tract and migrate to the urinary system through the periurethral area. This migration can occur via several routes, including improper hygiene practices, sexual activity, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tinea capitis in Germany. A survey in 1998.

Mycoses·2017

Same author

Multilocus microsatellite analysis of European and African Candida glabrata isolates.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2016

Same author

[Fungal infections].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2012

Same author

[Onychomycosis : a crown jewel of dermatology].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2012

Same author

[Fungal nail infections--an update: Part 1--Prevalence, epidemiology, predisposing conditions, and differential diagnosis].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2011

Same author

[Fungal nail infections - an update. Part 2 - From the causative agent to diagnosis - conventional and molecular procedures].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2011

Search research articles

Related Experiment Video

Updated: May 19, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

[Candida glabrata : pathogenicity and therapy update].

¹Institut für Pilzkrankheiten und Mikrobiologie, Luisenstr. 50, 10117, Berlin, Deutschland. tietz@institut-fuer-pilzkrankheiten.de

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete

|August 29, 2012

Summary

Chronic recurrent vulvovaginal candidiasis caused by Candida glabrata is challenging to treat. A new regimen combining micafungin and ciclopirox olamine successfully treated all 14 patients in this initial study.

More Related Videos

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy

Published on: March 29, 2024

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis

Published on: March 19, 2019

Related Experiment Videos

Last Updated: May 19, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy

Published on: March 29, 2024

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis

Published on: March 19, 2019

Area of Science:

Mycology
Infectious Diseases
Dermatology

Background:

Chronic recurrent vulvovaginal candidiasis (CR-VVC) due to Candida glabrata presents a significant therapeutic challenge.
Standard antifungal agents, including fluconazole, itraconazole, voriconazole, and posaconazole, frequently demonstrate limited efficacy against C. glabrata.
Micafungin, an echinocandin, exhibits broad-spectrum antifungal activity, including against less common Candida species, but its use in CR-VVC is unexplored.

Purpose of the Study:

To evaluate the efficacy of a novel therapeutic regimen for chronic recurrent vulvovaginal candidiasis caused by Candida glabrata.
To assess the safety and effectiveness of combining micafungin with topical ciclopirox olamine for difficult-to-treat vulvovaginal candidiasis.

Main Methods:

A cohort of 14 patients diagnosed with chronic recurrent vulvovaginal candidiasis attributed to Candida glabrata was enrolled.
Patients received a treatment regimen comprising systemic micafungin and topical ciclopirox olamine.
Treatment outcomes were assessed to determine the success rate of the combined therapy.

Main Results:

The novel therapeutic regimen involving micafungin and ciclopirox olamine demonstrated successful treatment in all 14 patients.
This combination therapy proved effective in managing chronic recurrent vulvovaginal candidiasis caused by the challenging pathogen Candida glabrata.

Conclusions:

The combination of micafungin and topical ciclopirox olamine represents a promising and effective therapeutic strategy for chronic recurrent vulvovaginal candidiasis caused by Candida glabrata.
Further clinical trials are warranted to confirm these initial findings and establish this regimen as a standard of care for refractory cases.